Chinese Herbal Medicines and Conventional Chronic Heart Failure Treatment for the Management of Chronic Heart Failure Complicated with Depression: A Systematic Review and Meta-Analysis

被引:5
|
作者
Yang, Peidan [1 ,2 ]
He, Jun [2 ]
机构
[1] Guangzhou Univ Chinese Med, Guangzhou 510405, Peoples R China
[2] Guangzhou Univ Chinese Med, Dept Rehabil Ctr, Affiliated Hosp 1, Guangzhou 510405, Peoples R China
基金
中国国家自然科学基金;
关键词
ST-JOHNS-WORT; THERAPY; RISK; MICROBIOTA; SURVIVAL; OUTCOMES; BIAS; TOOL;
D O I
10.1155/2020/8627928
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background. Combination therapy with Chinese herbal medicines (CHMs) and conventional medical treatment (CMT) was proposed as a therapeutic strategy for chronic heart failure (CHF) patients complicated with depression. Therefore, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess effects of this combination therapy on CHF complicated with depression. Methods. RCTs comparing the combination of CHMs and CMT to CMT were retrieved in seven electrical databases till March 30, 2019. The effective rate of cardiac function and Hamilton depression scale (HAMD) were marked as the primary outcomes. Left ventricular ejection fraction (LVEF) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) were marked as the secondary outcomes. The methodological quality of eligible RCTs used the Cochrane bias risk assessment tool. Stata 13.0 and Review Manager 5.3 were preferred for synthesizing the results if the results were appropriate. Results. Thirteen RCTs enrolling 1022 subjects met the inclusion criteria. The majority of the retrieved RCTs were evaluated to be of low methodological quality. The pooled results of the meta-analysis showed that CHMs plus CMT group created better outcomes compared to CMT alone therapy, as evidenced by the fact that the overall effects of combination therapy strategy were significantly greater than the control group in increasing effective rate of cardiac function (risk ratio (RR) = 1.28; 95% CI: 1.16 to 1.42), in improving depressive symptoms (HAMD) (standard mean difference (SMD) = -1.31; 95% CI: -1.68 to -0.95) and quality of life (MLHFQ) (weighted mean difference (WMD) = -8.42; 95% CI: -10.08 to -6.76), in increasing LVEF scores (WMD = 5.33; 95% CI: 4.30 to 6.35). Conclusion. The combination of CHMs and CMT increased the effective rate of cardiac function and LVEF scores and reduced HAMD and MLHFQ scale scores, which was a potential therapeutic strategy that improved the management of CHF patients complicated with depression. Future trials were needed to verify the above results since abnormal heterogeneity and poor quality of literature have existed in the included studies.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Efficacy and safety of dapagliflozin in the treatment of chronic heart failure A protocol for systematic review and meta-analysis
    Dong, Xueyan
    Ren, Lili
    Liu, Yueli
    Yin, Xuewei
    Cui, Siyuan
    Gao, Wulin
    Yu, Liming
    MEDICINE, 2021, 100 (26) : E26420
  • [22] Role of Telemedicine Intervention in the Treatment of Patients with Chronic Heart Failure: A Systematic Review and Meta-analysis
    Wang, Chaoqun
    Ba, Yanqun
    Ni, Jiajia
    Huang, Runzhi
    Du, Xiaofeng
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2024, 28 (04): : 177 - 187
  • [23] Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis
    Kai-Huan Wang
    Jia-Rui Wu
    Dan Zhang
    Xiao-Jiao Duan
    Meng-Wei Ni
    BMC Complementary and Alternative Medicine, 18
  • [24] Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis
    Wang, Kai-Huan
    Wu, Jia-Rui
    Zhang, Dan
    Duan, Xiao-Jiao
    Ni, Meng-Wei
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 18
  • [25] Lung ultrasound–guided management to reduce hospitalization in chronic heart failure: a systematic review and meta-analysis
    Mohammed Mhanna
    Azizullah Beran
    Salik Nazir
    Omar Sajdeya
    Omar Srour
    Hazem Ayesh
    Ehab A Eltahawy
    Heart Failure Reviews, 2022, 27 : 821 - 826
  • [26] Erythropoietin treatment in patients with chronic heart failure: a meta-analysis
    van der Meer, P.
    Groenveld, H. F.
    Januzzi, J. L., Jr.
    van Veldhuisen, D. J.
    HEART, 2009, 95 (16) : 1309 - 1314
  • [27] Telemonitoring in chronic heart failure: a meta-analysis
    Klersy, C.
    De Silvestri, A.
    Gabutti, G.
    Regoli, F.
    Auricchio, A.
    EUROPEAN HEART JOURNAL, 2009, 30 : 713 - 713
  • [28] Sildenafil for chronic heart failure : a meta-analysis
    Ariano, C.
    De Vecchis, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 254 - 254
  • [29] Ivabradine for the treatment of heart failure: A systematic review and meta-analysis
    Aljohani, Hadir
    Alkofide, Hadeel
    Aljohani, Hanin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 498 - 498
  • [30] ATORVASTATIN FOR CORONARY HEART DISEASE WITH CHRONIC HEART FAILURE IN CHINESE POPULATION: A META-ANALYSIS
    Nan, J.
    Huang, J.
    Yang, S.
    HEART, 2015, 101 : A32 - A32